For these studies, we chose the prostate cancer cell line LNCaP, in which the androgen-responsive gene TMPRSS2 and the ERG gene have been shown to undergo translocations in an androgen- and DNA-damage-responsive manner (Lin et al., 2009; Figures 5D and 5E), and this translocation event is frequently present in prostate cancers (Tomlins et al., 2005). This evidence concerns the gene TMPRSS2 and prostate carcinoma.